The Oxford-AstraZeneca vaccine is secure and efficient, researchers

In this September 9, 2020 image, a vaccine marked with a test tube can be seen in front of the AstraZeneca logo.

Given Ruvic | Reuters

LONDON – Developed by UK pharmaceutical company AstraZeneca in partnership with Oxford University, the coronavirus vaccine is the first whose late-stage study results have been independently reviewed and published in a medical journal.

The interim results from the Phase 3 studies with the Oxford-AstraZeneca vaccine were published in the Lancet on Tuesday. Peer review means that articles or studies are reviewed by other experts in the field before they are published and serve as an additional quality control measure on the results.

The study replicated the vaccine study results published a few weeks ago, which showed an average of 70% effectiveness in protecting against the coronavirus.

The two dosage regimens used were also repeated, with the two full doses exhibiting 62% effectiveness and 90% effectiveness demonstrated with the half-then-full dosage regimen.

This is breaking news. Please try again later.

Comments are closed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More